Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Acta Neurochir Suppl ; 88: 93-103, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-14531567

RESUMEN

PURPOSE: This was an open-label, dose-escalation trial of intratumoral administration of IL-4 Pseudomonas Exotoxin (NBI-3001) in patients with recurrent malignant glioma. PATIENTS AND METHODS: A total of 31 patients with histologically verified supratentorial grade 3 and 4 astrocytoma were studied. Of these, twenty-five patients were diagnosed with glioblastoma multiforme (GBM) while six were diagnosed with anaplastic astrocytoma (AA). Patients were over 18 years of age and had Karnofsky performance scores > or = 60. Patients were assigned to one of four dose groups in a dose-escalation fashion: 6 microg/ml x 40 ml, 9 microg/ml x 40 ml, 15 microg/ml x 40 ml, or 9 microg/ml x 100 ml of NBI-3001 administered intratumorally via stereotactically placed catheters. Patients were followed with serial MRI scans and clinical assessments every four weeks for the first 16 weeks and then every eight weeks until week 26. RESULTS: No drug-related systemic toxicity, as evident by lack of hematological or serum chemical changes, was apparent in any patients; treatment-related adverse effects were limited to the central nervous system. No deaths were attributable to treatment. Drug-related Grade 3 or 4 toxicity was seen in 39% of patients in all dose groups and 22% of patients at the maximum tolerated dose of 6 microg/ml x 40 ml. The overall median survival was 8.2 months with a median survival of 5.8 months for the GBM patients. Six-month survival was 52% and 48%, respectively. Gadolinium-enhanced magnetic resonance imaging of the brain showed areas of decreased signal intensity within the tumor consistent with tumor necrosis following treatment in many patients. CONCLUSIONS: NBI-3001 appears to have an acceptable safety and toxicity profile when administered intratumorally in patients with recurrent malignant glioma.


Asunto(s)
Astrocitoma/tratamiento farmacológico , Toxinas Bacterianas/administración & dosificación , Exotoxinas/administración & dosificación , Glioblastoma/tratamiento farmacológico , Inmunotoxinas/administración & dosificación , Interleucina-4/administración & dosificación , Recurrencia Local de Neoplasia/tratamiento farmacológico , Neoplasias Supratentoriales/tratamiento farmacológico , Adulto , Anciano , Astrocitoma/diagnóstico , Toxinas Bacterianas/efectos adversos , Quimioterapia Adyuvante , Terapia Combinada , Relación Dosis-Respuesta a Droga , Exotoxinas/efectos adversos , Femenino , Glioblastoma/diagnóstico , Humanos , Inmunotoxinas/efectos adversos , Infusiones Intralesiones , Interleucina-4/efectos adversos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia/diagnóstico , Estudios Prospectivos , Técnicas Estereotáxicas , Neoplasias Supratentoriales/diagnóstico
3.
Zentralbl Gynakol ; 118(12): 673-5, 1996.
Artículo en Alemán | MEDLINE | ID: mdl-9082705

RESUMEN

Report on a case of a highly malignant solitary lymphoma of the cervix uteri in a 51-year-old patient. The only noticeable finding leading to the diagnosis was the pathological result of the routine cervical smear. Solitary malignant lymphomas of the cervix must be seen as systemic diseases. They should therefore be treated by local surgical intervention and consecutive systemical chemotherapy in an interdisciplinary conception.


Asunto(s)
Linfoma Inmunoblástico de Células Grandes/diagnóstico , Linfoma no Hodgkin/diagnóstico , Neoplasias del Cuello Uterino/diagnóstico , Cuello del Útero/patología , Terapia Combinada , Femenino , Humanos , Lactante , Linfoma Inmunoblástico de Células Grandes/patología , Linfoma Inmunoblástico de Células Grandes/terapia , Linfoma no Hodgkin/patología , Linfoma no Hodgkin/terapia , Persona de Mediana Edad , Neoplasias del Cuello Uterino/patología , Neoplasias del Cuello Uterino/terapia , Frotis Vaginal
4.
J Cancer Res Clin Oncol ; 117 Suppl 4: S125-8, 1991.
Artículo en Inglés | MEDLINE | ID: mdl-1795000

RESUMEN

The oxazaphosphorine analog ifosfamide (IFO) has demonstrated an increased therapeutic index in a variety of solid tumors and hematologic malignancies compared with its parent compound cyclophosphamide. A fractionated dose schedule over 5 days as continuous infusion in combination with the uroprotective agent sodium-2-mercapto-ethane-sulfonate (mesna) is considered to provide an improved therapeutic/toxic ratio. Stability data of IFO demonstrate long-term stability for use in disposable infusion pumps as outpatient treatment. In all, 52 patients with various malignancies were entered in a feasibility study to receive outpatient continuous infusion of IFO. All patients were required to have a subcutaneous venous port system implanted. The following drug combinations were used: IFO as single agent, IFO/mitoxantrone, IFO/carboplatinum/etoposide, IFO/etoposide/MTX, IFO/epirubicin. Mitoxantrone and epirubicin were given as continuous infusion together with IFO. Starting dose of IFO was between 1.6-2.0 g/m2/day x 5 and was increased in absence of major hematologic or peripheral toxicity. Mesna was given in combination with IFO as continuous infusion at a dose of 50% of that calculated for IFO. No renal, bladder or central nervous system toxicity was observed. In 247 courses of outpatient continuous ifosfamide infusion only few technical complications due to improper handling were documented.


Asunto(s)
Atención Ambulatoria , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Ifosfamida/administración & dosificación , Neoplasias/tratamiento farmacológico , Adulto , Anciano , Carboplatino/administración & dosificación , Esquema de Medicación , Estabilidad de Medicamentos , Epirrubicina/administración & dosificación , Etopósido/administración & dosificación , Estudios de Factibilidad , Femenino , Humanos , Bombas de Infusión Implantables , Infusiones Intravenosas , Masculino , Mesna/administración & dosificación , Persona de Mediana Edad , Mitoxantrona/administración & dosificación
5.
Neurosurg Rev ; 12(1): 41-5, 1989.
Artículo en Inglés | MEDLINE | ID: mdl-2747932

RESUMEN

The authors emphasize that the maxillo-facial surgeon or otorhinolaryngologist should: 1. take part in diagnosing and planning the therapy of poly-traumatic patients. 2. operate simultaneously when possible. 3. try to provide immediate maxillo-facial surgical and/or otorhinolaryngologic treatment because of the great importance of early treatment for longterm functional and aesthetic results.


Asunto(s)
Traumatismos Craneocerebrales/cirugía , Fracturas Orbitales/cirugía , Fracturas Craneales/cirugía , Adulto , Lesiones Encefálicas/diagnóstico por imagen , Lesiones Encefálicas/cirugía , Traumatismos Craneocerebrales/diagnóstico por imagen , Femenino , Humanos , Masculino , Fracturas Orbitales/diagnóstico por imagen , Radiografía
8.
Fortschr Med ; 97(34): (1483-5), 1979 Sep 13.
Artículo en Alemán | MEDLINE | ID: mdl-499954

RESUMEN

In a study including a limited number of 33 patients with bacterial infections the use of doxycycline as a drip infusion of Vibramycin dry fill proved to have a good clinical effect. The bacteriological tests showed that 58% of the tetracycline-sensitive germs demonstrated before therapy had been eliminated and another 6% markedly reduced. Clinically very good or good results were achieved in 76% of the patients. Toleration was excellent in all cases.


Asunto(s)
Doxiciclina/uso terapéutico , Adulto , Relación Dosis-Respuesta a Droga , Doxiciclina/administración & dosificación , Evaluación de Medicamentos , Farmacorresistencia Microbiana , Tolerancia a Medicamentos , Femenino , Humanos , Infusiones Parenterales , Fallo Renal Crónico/tratamiento farmacológico , Enfermedades Pulmonares/tratamiento farmacológico , Masculino , Persona de Mediana Edad
9.
Klin Monbl Augenheilkd ; 171(6): 811-5, 1977 Dec.
Artículo en Alemán | MEDLINE | ID: mdl-342807

RESUMEN

The buildings of the clinics and institutions of the medical faculty in Münster which were planned in 1914 and completed in 1925 were enlarged considerably with numerous new buildings in the 1950's because of increasing specialisation in medicine. The university eye clinic built in 1925 was enlarged in 1970 by the addition of a bed wing and in 1975 by the new construction of the out patients department. In 1969 the foundation stone for the new central clinic with the four bed towers was laid. The eye clinic will not move into the new central clinic, because the old part of the present eye clinic was also completely renovated, besides the construction of both the additions. This description is complemented by conclusive data on the number and bed-use of the single clinics and on the cost of the new wing and the number of students.


Asunto(s)
Facultades de Medicina/historia , Alemania Occidental , Historia del Siglo XX , Arquitectura y Construcción de Hospitales/historia , Humanos , Oftalmología/historia , Universidades/historia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...